SEARCH

SEARCH BY CITATION

References

  • 1
    Sicinski P, Dionaher J, Parker S, Li T, Fazil A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995; 82: 62130.
  • 2
    Sicinski P, Weinberg RA. A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia 1997; 2: 33542.
  • 3
    Ahnstrom M, Nordenskjold B, Rutqvist L, Skoog L, Stal O. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 2005; 91: 14551.
  • 4
    Vos C, Ter Haar N, Peterse J, Cornelisse C, van de Vijver M. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 1999; 187: 27984.
  • 5
    Kenny F, Hui R, Musgrove E, Gee J, Blamey R, Nicholson R, Sutherland R, Robertson JF. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999; 5: 206977.
  • 6
    Ormandy C, Musgrove E, Hui R, Daly R, Sutherland R. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003; 78: 32335.
  • 7
    Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 1999; 96: 1121722.
  • 8
    Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001; 12: 3207.
  • 9
    Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 12957.
  • 10
    Ritke M, Bergoltz V, Allan W, Yalowich J. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol 1994; 48: 52533.
  • 11
    Lallemand D, Spyrou G, Yaniv M, Pfarr CM. Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 1997; 14: 81930.
  • 12
    Yang-Yen H, Zhang X, Graupner G, Tzukerman M, Sakamoto B, Karin M, Pfahl M. Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biol 1991; 3: 120619.
  • 13
    Kerr L, Inoue J, Verma I. Signal transduction: the nuclear target. Curr Opin Cell Biol 1992; 4: 496501.
  • 14
    Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996; 87: 92939.
  • 15
    Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 2000; 103: 897907.
  • 16
    Hill C, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995; 80: 199211.
  • 17
    Groom L, Sneddon A, Alessi D, Dowd S, Keyse S. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J 1996; 15: 362132.
  • 18
    Meriin A, Yaglom JA, Gabai VL, Zon L, Ganiatsas S, Mosser DD, Zon L, Sherman MY. Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72. Cell Biol 1999; 19: 254755.
  • 19
    Nguyen A, Hiozaki K. Heat-shock-induced activation of stress MAP kinase is regulated by threonine- and tyrosine-specific phosphatases. Genes Dev 1999; 13: 165363.
  • 20
    ElShamy WM, Livingston DM. Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol 2004; 6: 95467.
  • 21
    Furuta S, Jiang X, Gu B, Cheng E, Chen P, Lee W. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci USA 2005; 102: 917681.
  • 22
    Wei M, Grushko T, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade O. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005; 65: 106929.
  • 23
    Tomlinson G, Chen T, Stastny V, Virmani A, Spillman M, Tonk V, Blum J, Schneider N, Wistuba I, Shay J, Minna J, Gazdar A. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998; 58: 323742.
  • 24
    Yuan Y, Kim W, Han H, Lee J, Park H, Chung J, Kang S, Park J. Establishment and characterization of human ovarian carcinoma cell lines. Gynecol Oncol 1997; 66: 37887.
  • 25
    Nakuci N, Mahner M, DiRenzo J, ElShamy WM. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp Cell Res 2006; 312: 312031.
  • 26
    Menendez JA, Mehmi I, Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol 2005; 26: 64959.
  • 27
    Prall O, Sarcevic B, Musgrove E, Watts C, Sutherland R. Estrogen-induced activation of Cdk4and Cdk2 during G1-S phase progression is accompanied by increased cyclinD1expression and decreased cyclin-dependent kinase inhibitor association with cyclin E- Cdk2. J Biol Chem 1997; 272: 1088294.
  • 28
    Foster S, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996; 10: 48898.
  • 29
    Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker M, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17b-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 1996; 12: 231524.
  • 30
    Musgrove E, Lee C, Buckely M, Sutherland R. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994; 91: 80226.
  • 31
    Zwijsen R, Klompmaker R, Wientjens E, Kristel P, Van der Burg B, Michalides R. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol 1996; 16: 255460.
  • 32
    Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000; 19: 205668.
  • 33
    Brisson M, Foster C, Wipf P, Joo B, Tomko RJ,Jr, Nguyen T, Lazo JS. Independent mechanistic inhibition of Cdc25 phosphatases by a natural product caulibugulone. Mol Pharmacol 2007; 71: 18492.
  • 34
    Okada A, Ohta Y, Brody S, Iguchi T. Epithelial c-jun and c-fos are temporally and spatially regulated by estradiol during neonatal rat oviduct differentiation. J Endocrinol 2004; 182: 21927.
  • 35
    Alonso A, Saxena M, Williams S, Mustelin T. Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation. J Biol Chem 2001; 276: 476671.
  • 36
    Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson N, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004; 90: 19428.
  • 37
    Leonessa F, Boulay V, Wright A, Thompson E, Brunner N, Clarke R. The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. Acta Oncol 1992; 31: 11523.